+

WO2009026389A2 - Régulation de glp-1 et sglt-1 dans des cellules gastro-intestinales - Google Patents

Régulation de glp-1 et sglt-1 dans des cellules gastro-intestinales Download PDF

Info

Publication number
WO2009026389A2
WO2009026389A2 PCT/US2008/073756 US2008073756W WO2009026389A2 WO 2009026389 A2 WO2009026389 A2 WO 2009026389A2 US 2008073756 W US2008073756 W US 2008073756W WO 2009026389 A2 WO2009026389 A2 WO 2009026389A2
Authority
WO
WIPO (PCT)
Prior art keywords
sweet taste
mammal
potentiator
patient
sweet
Prior art date
Application number
PCT/US2008/073756
Other languages
English (en)
Other versions
WO2009026389A3 (fr
Inventor
Robert F. Margolskee
Soraya Shirazi-Beechey
Josephine Egan
Original Assignee
Mount Sinai School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School Of Medicine filed Critical Mount Sinai School Of Medicine
Priority to EP08798295A priority Critical patent/EP2197433A4/fr
Publication of WO2009026389A2 publication Critical patent/WO2009026389A2/fr
Publication of WO2009026389A3 publication Critical patent/WO2009026389A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • ⁇ -gustducin null mice are defective for secretion of GLP-I in response to lumenal glucose.
  • isolated duodenum and duodenal villi from ⁇ -gustducin null mice likewise show deficient release of GLP-I in response to glucose.
  • NCI-H716 enteroendocrine L cells we observed GPCR-mediated activation of ⁇ -gustducin by glucose and sucrose. Decreasing ⁇ -gustducin expression in NCI-H716 cells by siRNA resulted in decreased glucose-mediated GLP-I secretion.
  • RNA isolated from intestinal tissue by using the RNeasy Mini Kit with on-column DNase 1 digestion (Qiagen, Crawley, U.K.) was used for cDNA synthesis using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo(dT)i2-i8 primers.
  • cDNA was cleaned up by using the Machery-Nagel Nucleospin extract kit (AB Gene, Epsom, U.K.), and 50 ng of cDNA was used per reaction.
  • D-glucose uptake was initiated by the addition of 100 ⁇ l of incubation medium containing 100 mM NaSCN (or KSCN), 100 mM mannitol, 20 mM Hepes/Tris (pH 7.4), 0.1 mM MgSO 4 , 0.02% (wt/vol) NaN 3 , and 0.1 mM D-[U 14 C]glucose to BBMV (100 ⁇ g of protein).
  • incubation medium containing 100 mM NaSCN (or KSCN), 100 mM mannitol, 20 mM Hepes/Tris (pH 7.4), 0.1 mM MgSO 4 , 0.02% (wt/vol) NaN 3 , and 0.1 mM D-[U 14 C]glucose to BBMV (100 ⁇ g of protein).
  • Bound DIG-labeled probes were detected by 5 -min equilibration in digoxigenin-alkaline phosphatase (DIG-AP) buffer [100 mM Tris-HCl (pH 7.5)/150 mM NaCl], followed by 30- min block in DIG-AP buffer containing 1% (wt/vol) DIG blocking reagent (Roche), overnight incubation in DIG-AP buffer containing 1% (wt/vol) DIG blocking reagent and anti-DIG AP-conjugated antibody diluted 1 :1,000, 5-min wash in DIG-AP buffer, 5-min equilibration in NBT/BCIP buffer [100 mM Tris-HCl (pH 9.5)/100 mM NaCl/50 mM MgCl 2 ], 1-h incubation in the dark in NBT/BCIP buffer containing 10% polyvinyl alcohol and NBT/ BCIP mixture (Roche) diluted 1 :50, and 5-min wash in 10 m

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés comprenant l'administration d'inhibiteurs du goût sucré/de renchérisseurs du goût sucré. Plus précisément, la présente invention concerne des procédés destinés à réduire ou à inhiber l'absorption de glucides par un mammifère, à augmenter ou à induire l'absorption de glucides par un mammifère, à traiter un trouble associé à une insuffisance de l'absorption de glucides chez un patient, à réguler les taux de glycémie dans le sang chez un mammifère, à favoriser la sécrétion d'insuline chez un mammifère, à favoriser la perte de poids chez un mammifère, à favoriser la prise de poids chez un mammifère, à traiter l'obésité chez un patient et à traiter le diabète chez un patient.
PCT/US2008/073756 2007-08-20 2008-08-20 Régulation de glp-1 et sglt-1 dans des cellules gastro-intestinales WO2009026389A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08798295A EP2197433A4 (fr) 2007-08-20 2008-08-20 Régulation de glp-1 et sglt-1 dans des cellules gastro-intestinales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96546307P 2007-08-20 2007-08-20
US60/965,463 2007-08-20

Publications (2)

Publication Number Publication Date
WO2009026389A2 true WO2009026389A2 (fr) 2009-02-26
WO2009026389A3 WO2009026389A3 (fr) 2009-04-16

Family

ID=40378983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/073756 WO2009026389A2 (fr) 2007-08-20 2008-08-20 Régulation de glp-1 et sglt-1 dans des cellules gastro-intestinales

Country Status (2)

Country Link
EP (1) EP2197433A4 (fr)
WO (1) WO2009026389A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009027744A1 (de) 2009-07-15 2011-01-20 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Prekursor-Verbindungen von Süßrezeptor-Antagonisten zur Prävention oder Behandlung von Krankheiten
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EP2520647A4 (fr) * 2009-12-02 2013-07-10 Hasegawa T Co Ltd Construction d'expression de récepteur de goût sucré, corps cellulaire dans lequel celle-ci est exprimée, et usage de celle-ci
EP2629774A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
EP2630491A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
EP2629609A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
EP2629617A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
WO2019185387A1 (fr) * 2018-03-26 2019-10-03 Anglia Ruskin University Higher Education Corporation Traitement du cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1568380A4 (fr) * 2002-12-04 2009-10-21 Kissei Pharmaceutical Prevention ou traitement de maladies dues a l'hyperglycemie
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
JP5448297B2 (ja) * 2003-10-16 2014-03-19 テクコム・グループ・リミテッド・ライアビリティ・カンパニー 低減した血中応答を有する低減可消化炭水化物食物
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2197433A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2292224A1 (fr) 2009-07-15 2011-03-09 Symrise AG Liaisons de précurseur d'antagonistes à récepteur de saccharine pour la prévention ou le traitement du diabète
DE102009027744A1 (de) 2009-07-15 2011-01-20 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Prekursor-Verbindungen von Süßrezeptor-Antagonisten zur Prävention oder Behandlung von Krankheiten
US8592621B2 (en) 2009-07-15 2013-11-26 Symrise Ag Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
US8466114B2 (en) 2009-10-20 2013-06-18 Novartis Ag Glycoside derivatives and uses thereof
USRE49080E1 (en) 2009-10-20 2022-05-24 Novartis Ag Glycoside derivatives and uses thereof
US9895389B2 (en) 2009-10-20 2018-02-20 Novartis Ag Glycoside derivatives and uses thereof
US8828951B2 (en) 2009-10-20 2014-09-09 Novartis Ag Glycoside derivatives and uses thereof
EP2520647A4 (fr) * 2009-12-02 2013-07-10 Hasegawa T Co Ltd Construction d'expression de récepteur de goût sucré, corps cellulaire dans lequel celle-ci est exprimée, et usage de celle-ci
US8658383B2 (en) 2009-12-02 2014-02-25 T. Hasegawa Co., Ltd. Sweet taste receptor-expressing construct, cell body expressing the same, and utilization thereof
EP2629617A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
EP2629609A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
CN104220875A (zh) * 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
US9486463B2 (en) 2010-10-19 2016-11-08 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2630491A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
EP2629774A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
WO2019185387A1 (fr) * 2018-03-26 2019-10-03 Anglia Ruskin University Higher Education Corporation Traitement du cancer

Also Published As

Publication number Publication date
WO2009026389A3 (fr) 2009-04-16
EP2197433A2 (fr) 2010-06-23
EP2197433A4 (fr) 2010-09-08

Similar Documents

Publication Publication Date Title
WO2009026389A2 (fr) Régulation de glp-1 et sglt-1 dans des cellules gastro-intestinales
Bany Bakar et al. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Margolskee et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1
Parker et al. Molecular mechanisms underlying nutrient-stimulated incretin secretion
Jeon et al. SREBP-2 regulates gut peptide secretion through intestinal bitter taste receptor signaling in mice
Rubino et al. The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat
Baranowski Biological role of liver X receptors
Fang et al. Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1α/GLUT4 axis-mediated glucose consumption
Pedroso et al. Changes in leptin signaling by SOCS3 modulate fasting-induced hyperphagia and weight regain in mice
Sun et al. Ventromedial hypothalamic primary cilia control energy and skeletal homeostasis
Saqui-Salces et al. A high-fat diet regulates gastrin and acid secretion through primary cilia
Adriaenssens et al. Distribution and stimulus secretion coupling of enteroendocrine cells along the intestinal tract
Davis et al. Glucagon-like peptide-1: actions and influence on pancreatic hormone function
Han et al. Pancreatic islet APJ deletion reduces islet density and glucose tolerance in mice
Zhou et al. Inhibition of gastric motility by hyperglycemia is mediated by nodose ganglia KATP channels
Coskun et al. Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYY
Hu et al. Sestrin2 in POMC neurons modulates energy balance and obesity related metabolic disorders via mTOR signaling
Frutos et al. Pituitary alterations involved in the decline of growth hormone gene expression in the pituitary of aging rats
García-Martínez et al. Insulin drives glucose-dependent insulinotropic peptide expression via glucose-dependent regulation of FoxO1 and LEF1/β-catenin
Gribble et al. Glucagon-like peptide 1 (GLP-1)
US20090196878A1 (en) Intestinal epithelial glucose sensor
WO2011115106A1 (fr) Produit pharmaceutique pour la thérapie de pseudo-exercice
Freilich Effect of dietary nutrient profile on plasma glucagon-like peptide-2 in healthy cats
Lin The Role of Adiponectin in Gustatory Perception of Fat
Campbell The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08798295

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008798295

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载